Disease map-based biomarker selection and pre-validation for bladder cancer diagnostic

Abstract

Context: Urinary biomarkers are promising as simple alternatives to cystoscopy for the diagnosis of de novo and recurrent bladder cancer.

Objective: To identify a highly sensitive and specific biomarker candidate set with potential clinical utility in bladder cancer.

Materials and methods: Urinary biomarker concentrations were determined by ELISA. The performance of individual markers and marker combinations was assessed using ROC analysis.

Results: A five-biomarker panel (IL8, MMP9, VEGFA, PTGS2 and EN2) was defined from the candidate set.

Discussion and conclusion: This panel showed a better overall performance than the best individual marker. Further validation studies are needed to evaluate its clinical utility in bladder cancer.

• Biomarkers
• bladder cancer
• invasiveness
• recurrence

Declaration of interest

This work has been supported in part by the European Commission Program DIPROMON – HEALTH-F5-2012-306157-2: Development of an integrated protein- and cell-based device for non-invasive diagnostics in the urogenital tract. The authors report no declarations of interest.